Jasjit Suri PhD, MBA, FIEEE, FAIMBE, FAIUM, FSVM, FAPVS

Jasjit Suri, is an American industrialist, innovator, and chief technology officer. He has worked in the field of Biomedical Engineering, Computer Sciences, industrial computer engineering, software and hardware engineering, clinical and regulatory engineering, and its management. His work has been focused on the implementation of Artificial intelligence in Biomedicine, and Healthcare. He has been a fellow of AIMBE, AIUM, SVM, APVS, and IEEE. Suri has also led teams for 510(K) regulatory clearance of medical device products in healthcare. 

Suri is the son of Tarlochan S. Suri, a Jabalpur Engineering College graduate, and grandson of a Banaras Hindu University's electrical and mechanical engineering graduate, Udham S. Chadha. He got admission to Sainik School, Rewa, where he received the all-rounder award in 1981 and also represented his school in several extracurricular activities including debate, shooting, athletics, and boxing. 

In 1988, Suri received his bachelor's in electronics engineering from Maulana Azad College of Technology, Bhopal, followed by his MS degree in computer sciences from the University of Illinois, Chicago in 1991. Later in 1997, he completed his Ph.D. in electrical engineering at the University of Washington, Seattle. Suri was then selected and became one of the youngest fellows of AIMBE in 2001. He then joined the Weatherhead School of Management, Case Western Reserve University in 2002 and completed his MBA in 2004. 

Suri is also the recipient of the Director General’s President’s Gold medal and has been selected as a fellow of the Institute of Electrical and Electronic Engineering (IEEE), a fellow of the American Institute of Ultrasound in Medicine (AIUM), a fellow of the Society of Vascular Medicine (SVM), and a fellow of Asia Pacific Vascular Society (APVS) 

Suri began his career in 1990 and has been in the field of industrial computer engineering, computer sciences, biomedical engineering, software and hardware engineering, and its management. Some of his industrial work was with industries that include Larsen in Tubro (L&T), International Business Machines (IBM), Siemens Medical Systems (SMS), Philips Medical Systems (PMS), Fischer Imaging, Eigen, and AtheroPoint. 

He has developed biomedical vascular imaging technology with AtheroPoint LLC, Roseville, for Cardiovascular disease (CVD) and Stroke (large-vessel disease and small-vessel disease), covering over 150 peer-reviewed National Institute of Health international journals in Ultrasound, Computed Tomography (CT), and Magnetic resonance imaging (MRI) areas. In addition, Suri finished two clinical studies. First, he conducted an epidemiological trial of nearly 1000 patients using AtheroEdge 1.0, and second on patients with diabetes, renal disease, and Rheumatoid arthritis, and evaluated their 10-year risk predictions for CVD and stroke risk using AtheroEdge 2.0. He has published over 200 journals in the area of Atherosclerosis imaging, and cardiovascular ultrasound and has designed ten books majorly focused on carotid and coronary artery disease. His published contributions in the field of biomedical engineering include design, scientific verification and validation (V&V), risk analysis, Failure Mode Effect Analysis (FMEA), and clinical validations, leading to several FDA 510(K) clearances. 

Suri has also contributed to the field of Artificial intelligence (AI), machine learning, deep learning, and hybrid deep learning, primarily in the implementation of AI in the field of biomedicine, and published 100 AI peer-reviewed National Institute of Health international publications and four books in AI. His designs include AI-based multithreaded dual architectures for joint platforms such as mobile devices and desktops simultaneously. His recent work is in biased evaluations of AI systems and the design of “Unseen AI” vs. “Seen AI” systems for COVID, Parkinson's, and CVD. His career has focused on product development and has been active as a chief technology officer since 2004 for future product designs and building intellectual property portfolios. Suri has over 50 US and European patents. He has also managed operations in the healthcare medical device industry at CTO and COO levels and linked with several diagnostic centers around the globe. 

He developed Artemis, an image-guided surgery robotics device for three-dimensional sonography with needle tracking in the diagnosis and treatment of prostate cancer, and designed, and developed a system for prostate biopsy. His other products include AtheroEdge 3.0 for AI and Ultrasound-based cardiovascular risk assessment and coronary artery disease risk prediction, AtheroCloud for cloud-based CVD risk assessment, Atheromatic 2.0 for AI-based system for symptomatic vs. asymptomatic plaque tissue characterization and plaque vulnerability, Voyager, an image-guided surgery system for Neurology applications, DSAex 2000 - Digital Subtraction Angiography system, Breast uptake analysis system, for breast lesion detection using MRI, and more recently COVLIAS 1.0 for diagnosis of COVID-19 using CT. Suri is also a fellow of the IEEE-EMBS and a well-known speaker in the field of engineering in medicine and biology, especially in medical devices for healthcare markets.